Filgotinib may be associated with a lower risk of herpes zoster compared with other Janus kinase inhibitors in rheumatoid arthritis.

HSV type 1 reactivation was prevalent among critically ill patients with COVID-19 and was independently associated with ...

64 percent of people under 50 have HSV-1 – WHO’s report breaks down herpes symptoms, prevention, treatment, and why stigma is ...

Research has shown that the use of JAK inhibitors can weaken rheumatoid arthritis patients' responses to shingles vaccination ...

Recombinant zoster vaccine is highly effective and safe for patients with inflammatory rheumatic diseases receiving immunosuppressive therapies.

TAMPA, FL / ACCESS Newswire / July 31, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) (“DataMeds AI” or the “Company”), a Health IT company leveraging its artificial intelligence platform EinsteinRx ™ and ...

More than 80% of immunosuppressed patients with idiopathic inflammatory myopathy achieved seroconversion after receiving the recombinant zoster vaccine, according to data published in Arthritis Care & ...

New research suggests the two-dose Shingrix vaccine could also lower the risk of dementia, adding to its benefits for adults ...

Herpetic infection signals differ across targeted therapies for patients with AD, including for overall and type-specific herpetic infections.

Japan: In an exploratory randomized trial from Japan, patients with rheumatoid arthritis who started the JAK inhibitor ...

IGNYTE showed that patients with confirmed progression on an anti-PD-1-based regimen who received RP1 plus nivolumab had a 34% response rate, with a median duration of 24.8 months, and 15% of them ...

A randomized trial in patients with rheumatoid arthritis (RA) suggests that the timing of when a Janus kinase (JAK) inhibitor ...